Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.
The purpose of this study is to assess the pathological response rate in operable breast cancer patients treated by neoadjuvant combination: "FEC-Taxotere/Vectibix".
Pathological Response Rate
DRUG: vectibix|DRUG: fluorouracile|DRUG: Epirubicine|DRUG: cyclophosphamide|DRUG: docetaxel
To assess the rate of complete histological response, according to Chevallier's classification, after 24 weeks of treatment
the rate of complete histological response, according to Sataloff's classification; the rate of clinical, ultrasound, mammogram response, according to the WHO criteria; progression-free and overall survival; the tolerance., After 24 weeks of treatment, at surgery and at five years
The purpose of this study is to assess the pathological response rate in operable breast cancer patients treated by neoadjuvant combination: "FEC-Taxotere/Vectibix".